@article{052a78bcbd1f4731a28fb67f60433df5,
title = "Long-term avelumab in advanced non-small-cell lung cancer: Summaries and post hoc analyses from JAVELIN Solid Tumor",
abstract = "Background: This study examined patients with advanced non-small-cell lung cancer who received long-term avelumab (anti-PD-L1) in a large phase Ib trial (JAVELIN Solid Tumor). Methods: Patients receiving >2 years of avelumab were reviewed and exploratory descriptive analyses were conducted. Results: Individuals with varying baseline characteristics who had received up to 6 years of avelumab were reviewed. Overall, 37/340 (10.9%) had received ≥2 years of treatment; in this subgroup, best response was complete response in 5.4%, partial response in 59.5% and stable disease in 29.7%; 51.4% had continued treatment beyond disease progression. Conclusions: In this study, 11% of patients with advanced non-small-cell lung cancer received ≥2 years of avelumab treatment and experienced prolonged response or continued clinical benefit.",
keywords = "Clinical trials, Immunotherapy, Lung, Metastasis, Solid tumors",
author = "Borys Hrinczenko and Nicholas Iannotti and Sanjay Goel and David Spigel and Howard Safran and Taylor, {Matthew H.} and Jaafar Bennouna and Wong, {Deborah J.} and Karen Kelly and Claire Verschraegen and Marcis Bajars and Juliane Manitz and Mary Ruisi and Gulley, {James L.}",
note = "Funding Information: Medical writing support was provided by A Thippeswamy of ClinicalThinking and funded by Merck (CrossRef Funder ID: 10.13039/100009945) and Pfizer. Funding Information: This work was supported by Merck (CrossRef Funder ID: 10.13039/100009945), as part of an alliance between Merck and Pfizer. Employees of the sponsor are coauthors of this manuscript who contributed to the design, execution and interpretation of the analyses being reported, writing the report and the decision to submit the article for publication, along with other coauthors. B Hrinczenko received research funding from Amgen, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Endocyte and Merrimack Pharma. S Goel received research grant/funding from EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA. D Spigel received advisory/consultancy, research funding and travel/accommodation/expenses from AstraZeneca, Boehringer In-gelheim, Bristol Myers Squibb, Celgene, Eli Lilly, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Pfizer and Roche/Genentech; advisory/consultancy and research funding from AbbVie, Am-gen, Foundation Medicine, GSK, Nektar, Novartis and Takeda; advisory/consultancy from Evelo Therapeutics, Illumina, Mod-erna Therapeutics, PharmaMar, Precision Oncology and TRM Oncology; research funding from Acerta Pharma, OncoGenex, Aeglea BioTherapeutics, ARMO Biosciences, Astellas Pharma, Celldex, Clovis Oncology, Daiichi Sankyo, G1 Therapeutics, GRAIL, Ipsen, Millennium, Neon Therapeutics, Tesaro, Transgene and University of Texas Southwestern Medical Center - Simmons Cancer Center; and travel/accommodation/expenses from Genzyme, Intuitive Surgical, Purdue Pharma, Spectrum Pharmaceuticals and Sysmex. MH Taylor received honoraria, advisory/consultancy, speaker bureau, expert testimony and travel/accommodation/expenses from Eisai; and honoraria, advisory/consultancy and travel/accommodation/expenses from Array, ArQule, Inc., Bayer, Blueprint, Novartis and Loxo. J Bennouna received honoraria, advisory/consultancy, research grant/funding and travel/accommodation/expenses from AstraZeneca; honoraria, advisory/consultancy and travel/accommodation/expenses from Roche; honoraria and advisory/consultancy from Boehringer Ingelheim, Bristol Myers Squibb and MSD; and research grant/funding from Merck. DJ Wong received advisory/consultancy and research grant/funding from Bristol Myers Squibb and research grant/funding from Astellas, AstraZeneca, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, FSTAR, KURA Oncology, Lilly, MSD, Regeneron and Roche-Genentech. K Kelly received honoraria, advisory/consultancy, research grant/funding and travel/accommodation/expenses from Abbvie and Genentech; honoraria, advisory/consultancy and travel/accommodation/expenses from MSD; advisory/consultancy and travel/accommodation/expenses from AstraZeneca; advisory/consultancy and research grant/funding from EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, and Regeneron; advisory/consultancy from Pfizer; research grant/funding from Five Prime; travel/accommodation/expenses from Lilly; and licensing/royalties from UpToDate. M Bajars is an employee of Merck Healthcare KGaA, Darmstadt, Germany. J Manitz is an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA. At the time the study was conducted, M Ruisi was an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA. JL Gulley received research grant/funding from Astellas Medivation, Bavarian Nordic, Bristol Myers Squibb, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, ImmunityBio, MSD and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2022 The Authors.",
year = "2022",
month = apr,
doi = "10.2217/fon-2021-0930",
language = "English (US)",
volume = "18",
pages = "1333--1342",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "11",
}
